The mechanism by which patients with portal hypertension develop portal hypertensive ... of the free or wedged hepatic vein in hepatic cirrhosis. [22] Various studies have shown that the ...

Cirrhosis progresses in stages, from a compensated phase with few symptoms to a decompensated phase with serious ...

The most common cause of portal hypertension is cirrhosis of the liver, which is scarring that accompanies the healing of liver injury caused by hepatitis, alcohol, or other less common causes of ...

Treatment for portal hypertension in patients with cirrhosis is based on the use of β-blockers with or without organic nitrates; however, these agents are effective in less than 50% of patients ...

April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension ...

They develop in approximately 50% of people with portal hypertension, a severe complication of cirrhosis (liver scarring).

Iconic actor and filmmaker Manoj Kumar passed away at the age of 87, battling heart conditions and decompensated liver cirrhosis, which contributed to his already worsening health. Decompensated ...

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “In the U.S. approximately 5 million adults are affected by MASH cirrhosis and clinically significant portal ...

Forty-six patients, 32 males and 14 females with portal hypertension and cirrhosis, were evaluated. The mean age of these patients was 48 ± 12 years (mean ± SD). In 43.5% of cases, cirrhosis ...

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the ...